Medical Information | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Related Articles
Lymphoma Hub spotlight | SYMPHONY-1: A phase Ib/III trial of TAZ+Len+R in R/R FL
We summarize key results from the phase Ib/III SYMPHONY-1 trial of TAZ+Len+R vs Pbo+Len+R in patients with R/R FL.
inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL
During the 66th ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari about the latest updates from the inMIND…
The Scientific Education Support Team | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Lisocabtagene maraleucel receives positive CHMP opinion for the treatment of adult patients with R/R FL
Lisocabtagene maraleucel has received a positive CHMP opinion recommending its approval for patients with R/R FL, following positive results from the phase II TRANSCEND FL…
Novel and emerging treatment options for R/R DLBCL
We provide an overview of the approved and emerging therapeutic options for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL
During the 66th ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari about the latest updates from the inMIND…
Orphan drug designation granted to MB-105 for the treatment of R/R T-cell lymphoma
Following positive results from a phase I trial (NCT03081910), the FDA grants orphan drug designation to MB-105 for the treatment of relapsed/refractory T-cell lymphoma.
ASPEN: 5.8-year follow-up of zanubrutinib in patients with WM
We summarize key 5.8-year follow-up results from the phase III ASPEN trial evaluating the safety and efficacy of zanubrutinib in patients with WM.